Syndax Pharmaceuticals (NASDAQ:SNDX) Given New $41.00 Price Target at JPMorgan Chase & Co.

Syndax Pharmaceuticals (NASDAQ:SNDX - Free Report) had its price objective upped by JPMorgan Chase & Co. from $39.00 to $41.00 in a report published on Thursday morning,Benzinga reports. They currently have an overweight rating on the stock.

Several other brokerages also recently weighed in on SNDX. Citigroup cut their price target on Syndax Pharmaceuticals from $45.00 to $42.00 and set a "buy" rating on the stock in a research report on Tuesday, March 4th. StockNews.com lowered Syndax Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Saturday, November 23rd. HC Wainwright reiterated a "buy" rating and set a $51.00 price target on shares of Syndax Pharmaceuticals in a research report on Tuesday, March 4th. Finally, Scotiabank lowered their price objective on Syndax Pharmaceuticals from $18.00 to $16.00 and set a "sector perform" rating on the stock in a research report on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the company's stock. According to MarketBeat.com, Syndax Pharmaceuticals presently has an average rating of "Moderate Buy" and an average target price of $36.20.

Remove Ads

Syndax Pharmaceuticals Stock Up 0.1 %

Shares of Syndax Pharmaceuticals stock traded up $0.02 on Thursday, reaching $13.73. 1,018,889 shares of the stock were exchanged, compared to its average volume of 1,453,791. The business has a 50 day moving average price of $14.26 and a two-hundred day moving average price of $16.02. The firm has a market capitalization of $1.18 billion, a price-to-earnings ratio of -3.78 and a beta of 0.92. Syndax Pharmaceuticals has a twelve month low of $12.06 and a twelve month high of $25.07.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last announced its quarterly earnings data on Monday, March 3rd. The company reported ($1.10) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.79). The business had revenue of $7.68 million for the quarter, compared to analyst estimates of $86.32 million. Research analysts forecast that Syndax Pharmaceuticals will post -3.72 EPS for the current year.

Insider Activity

In related news, CEO Michael A. Metzger sold 13,288 shares of the firm's stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $15.50, for a total value of $205,964.00. Following the transaction, the chief executive officer now directly owns 300,121 shares of the company's stock, valued at approximately $4,651,875.50. This trade represents a 4.24 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Neil Gallagher sold 4,618 shares of the business's stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $15.50, for a total value of $71,579.00. Following the sale, the insider now owns 85,095 shares of the company's stock, valued at approximately $1,318,972.50. This trade represents a 5.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 21,683 shares of company stock worth $336,087 in the last quarter. Corporate insiders own 4.10% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. State Street Corp raised its position in shares of Syndax Pharmaceuticals by 4.1% in the third quarter. State Street Corp now owns 3,770,826 shares of the company's stock valued at $72,588,000 after buying an additional 148,491 shares during the last quarter. Soleus Capital Management L.P. grew its stake in Syndax Pharmaceuticals by 128.4% during the 4th quarter. Soleus Capital Management L.P. now owns 2,492,000 shares of the company's stock valued at $32,944,000 after acquiring an additional 1,401,016 shares in the last quarter. Assenagon Asset Management S.A. raised its holdings in Syndax Pharmaceuticals by 343.0% in the 4th quarter. Assenagon Asset Management S.A. now owns 2,064,456 shares of the company's stock valued at $27,292,000 after acquiring an additional 1,598,428 shares during the last quarter. Geode Capital Management LLC raised its holdings in Syndax Pharmaceuticals by 3.5% in the 3rd quarter. Geode Capital Management LLC now owns 1,977,082 shares of the company's stock valued at $38,066,000 after acquiring an additional 66,459 shares during the last quarter. Finally, Franklin Resources Inc. lifted its stake in Syndax Pharmaceuticals by 13.4% in the 3rd quarter. Franklin Resources Inc. now owns 1,763,277 shares of the company's stock worth $34,948,000 after purchasing an additional 208,043 shares in the last quarter.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).